Should I buy or sell Mesa Laboratories stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mesa Laboratories in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MLAB shares. View MLAB analyst ratings or view top-rated stocks .

What is Mesa Laboratories' stock price target for 2024?

1 Wall Street analysts have issued 12-month price objectives for Mesa Laboratories' stock. Their MLAB share price targets range from $130.00 to $130.00. On average, they anticipate the company's stock price to reach $130.00 in the next twelve months. This suggests a possible upside of 30.5% from the stock's current price. View analysts price targets for MLAB or view top-rated stocks among Wall Street analysts .

How have MLAB shares performed in 2024?

Mesa Laboratories' stock was trading at $104.77 at the beginning of 2024. Since then, MLAB stock has decreased by 4.9% and is now trading at $99.62. View the best growth stocks for 2024 here .

When is Mesa Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 24th 2024. View our MLAB earnings forecast .

How were Mesa Laboratories' earnings last quarter?

Mesa Laboratories, Inc. (NASDAQ:MLAB) issued its earnings results on Monday, February, 5th. The medical instruments supplier reported $1.46 earnings per share for the quarter, missing the consensus estimate of $1.47 by $0.01. The medical instruments supplier earned $53.47 million during the quarter, compared to the consensus estimate of $54.90 million. Mesa Laboratories had a net margin of 0.45% and a trailing twelve-month return on equity of 7.41%.

How often does Mesa Laboratories pay dividends? What is the dividend yield for Mesa Laboratories?

Mesa Laboratories declared a quarterly dividend on Tuesday, April 2nd. Investors of record on Friday, May 31st will be paid a dividend of $0.16 per share on Friday, June 14th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date of this dividend is Friday, May 31st. Read our dividend analysis for MLAB .

Is Mesa Laboratories a good dividend stock?

Mesa Laboratories (NASDAQ:MLAB) pays an annual dividend of $0.64 per share and currently has a dividend yield of 0.62%. The dividend payout ratio is 376.49%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, MLAB will have a dividend payout ratio of 8.90% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for MLAB .

What ETFs hold Mesa Laboratories' stock?

ETFs with the largest weight of Mesa Laboratories (NASDAQ:MLAB) stock in their portfolio include Motley Fool Small-Cap Growth ETF (TMFS) . MFAM Small-Cap Growth ETF (MFMS) .

What is Gary Owens' approval rating as Mesa Laboratories' CEO?

5 employees have rated Mesa Laboratories Chief Executive Officer Gary Owens on Glassdoor.com . Gary Owens has an approval rating of 51% among the company's employees. This puts Gary Owens in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Mesa Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesa Laboratories investors own include NVIDIA (NVDA) , Verizon Communications (VZ) , Intel (INTC) , Alibaba Group (BABA) , Altria Group (MO) , Micron Technology (MU) , Exxon Mobil (XOM) , AbbVie (ABBV) , Advanced Micro Devices (AMD) and Becton, Dickinson and Company (BDX) .

Who are Mesa Laboratories' major shareholders?

Mesa Laboratories' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.10%) and Allspring Global Investments Holdings LLC (0.09%). Insiders that own company stock include Brian David Archbold , David M Kelly , Evan Guillemin , Gary M Owens , Gregory Dinoia , John Bradley Schmieder , John James Sullivan , John Sakys and Shannon Hall. View institutional ownership trends .

How do I buy shares of Mesa Laboratories?

Shares of MLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:MLAB

Mesa Laboratories (MLAB) Stock Price, News & Analysis

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

Free MLAB Stock Alerts

$99.62

-1.52 (-1.50%)

(As of 04/18/2024 ET)

Compare

Today's Range: $99.54
▼
$103.32
50-Day Range: $90.86
▼
$114.10
52-Week Range: $82.86
▼
$178.64

Volume: 31,078 shs
Average Volume: 49,112 shs
Market Capitalization: $536.95 million

P/E Ratio: 586.03
Dividend Yield: 0.64%
Price Target: $130.00

Get Mesa Laboratories alerts:

Mesa Laboratories MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 30.5% Upside
$130.00 Price Target
Short Interest: Healthy
3.54% of Shares Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 16.91%
From $6.15 to $7.19 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.52 out of 5 stars

Medical Sector

257th out of 918 stocks

Process Control Instruments Industry

8th out of 12 stocks

3.5

Analyst's Opinion

Consensus Rating
Mesa Laboratories has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Mesa Laboratories has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.54% of the outstanding shares of Mesa Laboratories have been sold short.
Short Interest Ratio / Days to Cover
Mesa Laboratories has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Mesa Laboratories has recently decreased by 2.70%, indicating that investor sentiment is improving.

0.8

Dividend Strength

Dividend Yield
Mesa Laboratories has a dividend yield of 0.62%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Mesa Laboratories does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Mesa Laboratories is 376.49%. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, Mesa Laboratories will have a dividend payout ratio of 8.90% next year. This indicates that Mesa Laboratories will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MLAB.

2.6

News and Social Media Coverage

News Sentiment
Mesa Laboratories has a news sentiment score of 1.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Mesa Laboratories this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Mesa Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mesa Laboratories insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.20% of the stock of Mesa Laboratories is held by insiders.
Percentage Held by Institutions
90.60% of the stock of Mesa Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Mesa Laboratories are expected to grow by 16.91% in the coming year, from $6.15 to $7.19 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Mesa Laboratories is 586.03, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 144.15.
Price to Earnings Ratio vs. Sector
The P/E ratio of Mesa Laboratories is 586.03, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 254.29.
Price to Book Value per Share Ratio
Mesa Laboratories has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Mesa Laboratories Stock (NASDAQ:MLAB)

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. The Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in various therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, and oncology related applications. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enable customers to automate chemical synthesis of peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The Calibration Solutions segment designs, manufactures, and markets quality control products to measure or calibrate temperature, pressure, pH, and humidity for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

MLAB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MLAB Stock News Headlines

April 18, 2024 | finance.yahoo.com

The past three years for Mesa Laboratories (NASDAQ:MLAB) investors has not been profitable

April 8, 2024 | globenewswire.com

MESA LABS ANNOUNCES AMENDMENT TO CREDIT FACILITY AND REPURCHASE OF SENIOR CONVERTIBLE NOTES

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 4, 2024 | globenewswire.com

MESA LABS DECLARES QUARTERLY DIVIDEND

April 1, 2024 | globenewswire.com

Mesa Laboratories, Inc. to Announce Unaudited Fourth Quarter and Full Fiscal Year 2024 Results on May 24, 2024

March 15, 2024 | globenewswire.com

Mesa Labs Releases Second Annual Responsible Business Program Brochure

February 29, 2024 | wsj.com

Mesa Laboratories Inc.

February 23, 2024 | benzinga.com

Mesa Laboratories Stock (NASDAQ:MLAB) Dividends: History, Yield and Dates

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 19, 2024 | finance.yahoo.com

Mesa Laboratories (MLAB) Impacted by Slowdown in Pharmaceutical And Biotech Spending

February 8, 2024 | finance.yahoo.com

Results: Mesa Laboratories, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

February 5, 2024 | markets.businessinsider.com

Here's what Wall Street expects from Mesa Laboratories's earnings

February 5, 2024 | msn.com

Mesa Laboratories Non-GAAP EPS of $2.02 beats by $0.32, revenue of $53.47M misses by $1.13M

February 5, 2024 | finance.yahoo.com

Mesa Laboratories Inc (MLAB) Faces Revenue Dip Amidst Strategic Acquisitions

February 5, 2024 | finance.yahoo.com

Mesa Labs (MLAB) Lags Q3 Earnings and Revenue Estimates

February 2, 2024 | benzinga.com

Earnings Preview: Mesa Laboratories

January 24, 2024 | seekingalpha.com

Andvari Associates Q4 2023 Letter

January 5, 2024 | benzinga.com

Mesa Laboratories Stock (NASDAQ:MLAB), Analyst Ratings, Price Targets, Predictions

January 5, 2024 | msn.com

Evercore ISI Group Upgrades Mesa Laboratories (MLAB)

January 5, 2024 | finance.yahoo.com

What Is Mesa Laboratories, Inc.'s (NASDAQ:MLAB) Share Price Doing?

January 4, 2024 | markets.businessinsider.com

Evercore ISI Group Upgrades Mesa Laboratories: Here's What You Need To Know

January 3, 2024 | finanznachrichten.de

Mesa Laboratories, Inc.: Mesa Labs Completes the Acquisition of GKE Science & Technology Co.

January 3, 2024 | finance.yahoo.com

Mesa Labs Completes the Acquisition of GKE Science & Technology Co.

December 27, 2023 | morningstar.com

Mesa Laboratories Inc MLAB

December 14, 2023 | finance.yahoo.com

Mesa Laboratories, Inc. to Announce Second Quarter Results on February 5, 2024

November 6, 2023 | finance.yahoo.com

Mesa Laboratories Inc (MLAB) Reports 9.5% Decrease in Q2 FY 2024 Revenues

October 25, 2023 | finance.yahoo.com

Mesa Laboratories, Inc. (MLI.F)

See More Headlines

Receive MLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesa Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/05/2024
Ex-Dividend for 3/15 Dividend: 2/28/2024
Dividend Payable: 3/15/2024
Today: 4/19/2024
Next Earnings (Confirmed): 5/24/2024
Ex-Dividend for 6/14 Dividend: 5/31/2024
Dividend Payable: 6/14/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Process control instruments
Sub-Industry: Electronic Equipment & Instruments
Current Symbol: NASDAQ:MLAB
CUSIP: 59064R10
CIK: 724004
Web: www.mesalabs.com
Phone: (303) 987-8000
Fax: 303-987-8989
Employees: 698
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $130.00
High Stock Price Target: $130.00
Low Stock Price Target: $130.00
Potential Upside/Downside: +30.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.17
Trailing P/E Ratio: 586.03
Forward P/E Ratio: 16.20
P/E Growth: N/A
Net Income: $930,000.00
Net Margins: 0.45%
Pretax Margin: -0.28%
Return on Equity: 7.41%
Return on Assets: 4.34%

Debt

Debt-to-Equity Ratio: 0.58
Current Ratio: 2.68
Quick Ratio: 1.86

Sales & Book Value

Annual Sales: $219.08 million
Price / Sales: 2.45
Cash Flow: $11.56 per share
Price / Cash Flow: 8.62
Book Value: $73.60 per share
Price / Book: 1.35

Miscellaneous

Outstanding Shares: 5,390,000
Free Float: 5,114,000
Market Cap: $536.95 million
Optionable: Not Optionable
Beta: 0.83

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MLAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Mesa Laboratories stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mesa Laboratories in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MLAB shares.
View MLAB analyst ratings or view top-rated stocks.
What is Mesa Laboratories' stock price target for 2024?: 1 Wall Street analysts have issued 12-month price objectives for Mesa Laboratories' stock. Their MLAB share price targets range from $130.00 to $130.00. On average, they anticipate the company's stock price to reach $130.00 in the next twelve months. This suggests a possible upside of 30.5% from the stock's current price.
View analysts price targets for MLAB or view top-rated stocks among Wall Street analysts.
How have MLAB shares performed in 2024?: Mesa Laboratories' stock was trading at $104.77 at the beginning of 2024. Since then, MLAB stock has decreased by 4.9% and is now trading at $99.62.
View the best growth stocks for 2024 here.
When is Mesa Laboratories' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 24th 2024.
View our MLAB earnings forecast.
How were Mesa Laboratories' earnings last quarter?: Mesa Laboratories, Inc. (NASDAQ:MLAB) issued its earnings results on Monday, February, 5th. The medical instruments supplier reported $1.46 earnings per share for the quarter, missing the consensus estimate of $1.47 by $0.01. The medical instruments supplier earned $53.47 million during the quarter, compared to the consensus estimate of $54.90 million. Mesa Laboratories had a net margin of 0.45% and a trailing twelve-month return on equity of 7.41%.
How often does Mesa Laboratories pay dividends? What is the dividend yield for Mesa Laboratories?: Mesa Laboratories declared a quarterly dividend on Tuesday, April 2nd. Investors of record on Friday, May 31st will be paid a dividend of $0.16 per share on Friday, June 14th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date of this dividend is Friday, May 31st.
Read our dividend analysis for MLAB.

Is Mesa Laboratories a good dividend stock?: Mesa Laboratories (NASDAQ:MLAB) pays an annual dividend of $0.64 per share and currently has a dividend yield of 0.62%. The dividend payout ratio is 376.49%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, MLAB will have a dividend payout ratio of 8.90% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MLAB.
What ETFs hold Mesa Laboratories' stock?: ETFs with the largest weight of Mesa Laboratories (NASDAQ:MLAB) stock in their portfolio include Motley Fool Small-Cap Growth ETF (TMFS).MFAM Small-Cap Growth ETF (MFMS).
What is Gary Owens' approval rating as Mesa Laboratories' CEO?: 5 employees have rated Mesa Laboratories Chief Executive Officer Gary Owens on Glassdoor.com. Gary Owens has an approval rating of 51% among the company's employees. This puts Gary Owens in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Mesa Laboratories own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Mesa Laboratories investors own include NVIDIA (NVDA), Verizon Communications (VZ), Intel (INTC), Alibaba Group (BABA), Altria Group (MO), Micron Technology (MU), Exxon Mobil (XOM), AbbVie (ABBV), Advanced Micro Devices (AMD) and Becton, Dickinson and Company (BDX).
Who are Mesa Laboratories' major shareholders?: Mesa Laboratories' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.10%) and Allspring Global Investments Holdings LLC (0.09%). Insiders that own company stock include Brian David Archbold, David M Kelly, Evan Guillemin, Gary M Owens, Gregory Dinoia, John Bradley Schmieder, John James Sullivan, John Sakys and Shannon Hall.
View institutional ownership trends.
How do I buy shares of Mesa Laboratories?: Shares of MLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MLAB) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial